Evidence map›Paper›PMID 36119068›Full record

ArticleFrontiers in immunology2022

A robust CD8

Jinteng Feng, Longwen Xu, Shirong Zhang, Luying Geng, Tian Zhang, Yang Yu, Rui Yuan, Yusheng He, Zhuhui Nan, Min Lin and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jinteng FengDepartment of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Longwen XuDepartment of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Shirong ZhangDepartment of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Luying GengDepartment of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Tian ZhangDepartment of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yang YuDepartment of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Rui YuanDepartment of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yusheng HeDepartment of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Zhuhui NanDepartment of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Min LinBioinspired Engineering and Biomechanics Center (BEBC), Xi'an Jiaotong University, Xi'an, China.
Hui GuoDepartment of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
First Affiliated Hospital of Xi'an Jiaotong University · CNXi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with stage III lung adenocarcinoma (LUAD) have significant survival heterogeneity, meanwhile, CD8

Indexed as

Adenocarcinoma of LungLung NeoplasmsCD8-Positive T-LymphocytesHumansImmunotherapyKaplan-Meier EstimatePrognosisUbiquitin-Protein LigasesARIH1 protein, humanUbiquitin-Protein LigasesCD8+ T cellclassifierimmunotherapylung adenocarcinomaprognosis

Identifiers

PMID36119068
PMCPMC9471021
OpenAlexW4293771221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.